Below are two abstracts and figures regarding the outcome in long term Vedolizumab use in Crohn or Colitis. Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol 2017;52:722–9. Objectives: Clinical ..
Tag : Colitis
Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis) Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant ..
Related articles:*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines ..
Effects of Withdrawal of Immunomodulators or Biologic Agents IBD Withdrawal of IBD (Inflammatory Bowel Disease) therapy; for example anti-TNF. 50% or more of patients with IBD who cease/stop therapy have a disease relapse. The decision to withdraw a drug should be made for each individual based on patient preference, disease markers, consequences of relapse, safety, ..
Checkpoint inhibitor colitis. ESMO guideline 2017 Grover, S., Rahma, O. E., Hashemi, N., & Lim, R. M. (2018). Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. American Society of Clinical Oncology Educational Book, (38), 13–19.doi:10.1200/edbk_100013 Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., … Larkin, J. (2017). Management of ..
Mild-to-Moderate Ulcerative Colitis – AGA guideline Related articles:*Acute severe colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin ..
MAYO Classification (Colitis Ulcerosa) Related articles:*Montreal classification (Crohn)*IBD Surveillance guidelines (Dutch)*Rutge..
Recent Comments